Legal Issues

StatSure, Chembio agree to end litigation, enter agreement to market HIV barrel technology

Published in AIDS Weekly, October 30th, 2006

StatSure Diagnostic Systems, Inc. (SSUR) and Chembio Diagnostics, Inc. (CEMI) announced that they have entered into a series of agreements that provide Inverness Medical Innovations, Inc. (IMA) with exclusive worldwide marketing rights to Chembio's Sure Check HIV 1/2 product for the detection of HIV 1 and 2 antibodies.

This rapid, point-of-care test, which is U.S. Food and Drug Administration (FDA)-cleared, utilizes StatSure's patented barrel technology, designed to provide safe, accurate and integrated single-use, rapid HIV antibody screening, and to minimize exposure to infectious agents; it will be exclusively manufactured by Chembio for Inverness'...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2006-10-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry